MSLE
Satellos Bioscience Inc

253
Mkt Cap
$111.92M
Volume
97,542.00
52W High
$13.39
52W Low
$4.53
PE Ratio
-4.61
MSLE Fundamentals
Price
$7.24
Prev Close
$8.01
Open
$7.81
50D MA
$10.20
Beta
0.09
Avg. Volume
56,786.95
EPS (Annual)
-$2.14
P/B
3.28
Rev/Employee
$0.00
$17.67
Loading...
Loading...
News
all
press releases
Satellos Bioscience (NASDAQ:MSLE) Downgraded to "Strong Sell" Rating by Wall Street Zen
Wall Street Zen downgraded Satellos Bioscience to a "strong sell" rating in a research note on Saturday...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
Satellos Bioscience (NASDAQ:MSLE) Now Covered by Cantor Fitzgerald
Cantor Fitzgerald assumed coverage on shares of Satellos Bioscience in a report on Wednesday. They set an "overweight" rating on the stock...
MarketBeat·10d ago
News Placeholder
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (Satellos or the Company), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today...
Business Wire·25d ago
News Placeholder
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (Satellos or the Company), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today...
Business Wire·1mo ago
News Placeholder
Satellos to Participate in Upcoming Investor Conferences
Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (Satellos or the Company), a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle...
Business Wire·1mo ago
News Placeholder
Why MSLE Stock Gave Up All Nasdaq Debut Gains And Fell 8% After Hours
SAT-3247, an oral therapy aimed at restoring muscle repair, is now in Phase 2 testing in children with DMD.
Stocktwits·1mo ago
News Placeholder
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters Option to Purchase Additional Shares
Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (Satellos or the Company), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today...
Business Wire·1mo ago
News Placeholder
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States
Satellos Bioscience Inc. (TSX: MSCL, Nasdaq: MSLE) (Satellos or the Company), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today...
Business Wire·1mo ago
<
...
1
>

Latest MSLE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.